Article

Adherence to Antihypertensive and Lipid-lowering Therapy - Impact on Clinical Practice

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.

  • Views: 1306

  • Likes: 0

  • Downloads: 21

  • Citations: 4

Average (ratings)
No ratings
Your rating

DOI:https://doi.org/10.15420/ecr.2008.4.2.10

Acknowledgements:This supplement was funded by Pfizer Inc. The authors kindly acknowledge the contribution of Gareth Worthington for medical writing assistance in the preparation of this manuscript, with financial support from Pfizer Inc.

Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

According to data provided by the National Center for Health Statistics (NCHS), life expectancy in the US increased by six years between 1970 and 2000.1,2 Much of this increase can be attributed to reductions in mortality due to cardiovascular (CV) disease (CVD).2 Similarly, the incidence of CVD-related mortality and morbidity has been falling steadily across the EU since the early 1980s, in contrast to some countries in Eastern Europe.3 Despite this reduction in CVD-related mortality rates, CVD remains the main cause of death in Europe today, accounting for more than 4.3 million deaths each year.3 In total, 48% of all deaths reported in Europe (54% in women and 43% in men) are the result of CVD.3 In particular, coronary heart disease (CHD) and stroke are the most common causes of death in Europe, accounting for 1.92 and 1.24 million deaths per year, respectively.3

There are many reasons that rates of CVD-related mortality remain high despite rapid developments in therapeutic strategies. First, diagnosis of CVD is often suboptimal. For example, up to one-third of myocardial infarctions go unrecognised but are associated with a prognosis almost as poor as for individuals surviving symptomatic infarctions.4 In addition, many seemingly healthy individuals may have a risk of CVD as high as those who already have clinically manifest disease, but are not enrolled in primary prevention programmes.5 A second likely reason for high mortality rates is that patients identified with established CVD, or patients identified as being at risk of developing CVD, are not receiving ideal medical management.6 This is illustrated by a recent survey of risk factor management in 3,876 patients with CHD in Europe – European Action on Secondary Prevention through Intervention to Reduce Events (EUROASPIRE III) – which demonstrated that 54% of patients had not achieved target blood pressure (BP) levels and 41% of patients had not achieved target low-density lipoprotein cholesterol (LDL-C) levels.7 The reasons underlying these disappointing data are not fully understood but underprescription of efficacious cardioprotective pharmacological interventions (e.g. statins)8 is likely to be an important factor.

Although current guidelines take into account all major risk factors and strive to target patients who would benefit from therapeutic intervention, considerable discrepancies exist between guideline recommendations and clinical practice, often leading to under-treatment of patients.9 A third important reason for high CVD-related mortality is medication non-adherence, defined as a patient’s failure to follow a prescribed drug regimen. Non-adherence rates to pharmacological therapy is a major issue across various chronic diseases.10 Concerning CVD specifically, the World Health Organization (WHO) describes poor adherence as the single most important cause of uncontrolled, treated hypertension (HTN).11 Indeed, the rate of adherence to antihypertensive medication is estimated to be just over 50% in the US.12 Similarly, a recent meta-analysis of studies reporting patient adherence or persistence with CV medications revealed that 49% were non-adherent to lipid-lowering therapies.13

Clearly, there is a need to understand why patients may not adhere to prescribed treatment interventions and to develop strategies to increase adherence rates, thus improving overall clinical outcomes. In this article, we review the clinical and economic implications of non-adherence focusing on antihypertensive and lipid-lowering medications. We also consider possible strategies that may improve the adherence of patients to treatment.

Reasons for Non-adherence to Medication in Cardiovascular Disease

Reasons for non-adherence to pharmacological therapy can roughly be grouped under three main headings: patient-, physician- and medication-related (see Table 1).

Patient-related Reasons

There are a number of direct patient-related reasons for non-adherence to antihypertensive and lipid-lowering medicines.14–22 These include: forgetfulness (which is the primary reason cited by patients for non-adherence);15 a negative attitude towards medication; frustration with poor therapeutic responses; pre-conceived beliefs regarding health and medication; cultural beliefs; lack of education/inadequate literacy skills; and poor language proficiency. In addition, a poor understanding of the cost–benefit of a prescribed drug, including a lack of understanding of the benefit of the medication and a fear of drug-related adverse events, may also contribute to patient non-adherence.

Inadequate follow-up by physicians may compound the problem by sending out the message to patients that adherence to medication is unimportant. Patient-related reasons may be grouped into two simple categories: passive and active non-adherence. Passive non-adherence may include merely forgetting to take medication, perhaps because of a busy work or social life. Active non-adherence, on the other hand, is a conscious decision by the patient to ‘self-medicate’; that is, decide for themselves the dose and frequency of their treatment regimen. In both cases, patients require education regarding the need to follow prescribed treatment regimens as directed.

Currently, conflicting data from different studies have resulted in uncertainty regarding how some demographic factors influence adherence to antihypertensives and lipid-lowering therapies. For example, many studies suggest that adherence rates may be higher in older patients than younger patients,19,23–29 while other data suggest that the reverse may be true.30,31 Similarly, many but not all studies suggest that adherence is lower in women than men.25,29,32–37 However, there is consensus that certain demographic factors are associated with poor adherence to medication. Adherence tends to be lower in patients of non-Caucasian origin (e.g. African-American, Hispanic and Asian- Pacific patients) than in Caucasian patients, resulting in higher rates of uncontrolled, treated HTN or hyperlipidaemia in these patient subgroups.19,25,26,38–45 The presence of one or more non-CV co-morbidities (e.g. depression, respiratory disease, gastrointestinal disorders or osteoarthritis) also appears to negatively influence treatment adherence, particularly in elderly patients.26,37,40,46–48

Physician-related Reasons

Poor communication between physician and patient is a significant problem that may influence the adherence of patients to medication.14,25,49,50 As outlined above, one barrier to adherence is the lack of knowledge regarding why a particular treatment regimen has been prescribed and the consequences of not adhering to the intervention. This problem is compounded by the fact that physicians tend to overestimate public understanding of the impact of CV risk factor management on overall health. For example, in a survey that investigated perceptions of CHD from the viewpoint of both physicians and the general public (Reassessing European Attitudes about Cardiovascular Treatment [REACT] study), 92% of physicians believed that their patients were aware that cholesterol is associated with CVD,5 whereas only 51% of the general public knew that high cholesterol was associated with CHD.51

Moreover, only 45% of general public surveyed were aware that CHD was the leading cause of death in their country. These findings suggest that physicians’ perceptions of risk factor management may not reflect clinical reality in their patients. Indeed, in another recent survey in Europe, physicians estimated that over 60% of their hypertensive patients had controlled BP.52 In reality, less than 30% of hypertensive patients in Europe have controlled BP (BP<140/90mmHg for non-diabetic patients; BP<130/80mmHg for diabetic patients) according to a recent study.53

This gap in patient–physician communication may, in part, be due to the increasingly limited time physicians have available to spend with each patient. In the REACT study,5 time-constraints were identified as the largest single barrier to preventative cardiology. This was particularly true in the UK, where physicians reported the highest monthly consultation rates of all the countries surveyed.5

In addition to the communication gaps between patients and physicians, poor communication between primary and secondary care physicians may also be an issue. It has been suggested that cardiologists may mistakenly presume that the primary care physician will manage the follow-up care of the patient and monitoring of CV risk factors. As a consequence, the primary care physician may perceive this lack of treatment plan to mean that the cardiologist does not believe a risk-lowering strategy is necessary.54 Ultimately, this breakdown in communication means that the outpatient is not properly informed about their condition and is poorly cared for.

Another phenomenon, known as clinical inertia, is rapidly becoming recognised as a barrier to optimal clinical outcomes. Clinical inertia can be thought of as the failure of a physician to intensify medication in patients who are not achieving goals that they are set. This is intrinsically related to non-adherence as the physician has to judge whether the set treatment goals are not being achieved due to an insufficient therapeutic dose or through failure on behalf of the patient to adhere to the treatment regimen as prescribed. In fact, both factors need to be considered. This was demonstrated in a retrospective cohort study of patients with coronary disease (n=10,447) evaluating the impact of medication non-adherence and therapy intensification on reaching target BP goals. In this study, medication non-adherence (odds ratio [OR] 1.73; 95% confidence interval [CI] 1.34–2.24) and therapy intensification (OR 1.31; 95% CI 1.01–1.70) were associated with having uncontrolled BP compared with having high systolic BP that became controlled over time.55

While the concept of considering medication intensification and non-adherence together might seem obvious, the paucity of clinical evidence to support the notion means that this is not often applied in clinical practice. For example, in a retrospective cohort study of 38,327 hypertensive patients who had filled prescriptions for one or more BP medications at Veterans’ Affairs (VA) healthcare facilities in a midwestern VA administrative region, providers only intensified medications in response to 30% of the 68,610 elevated BP events. In this study, there was almost no variation in intensification regardless of whether patients had good or poor BP medication adherence.56

Medication-related Reasons

Complicated drug regimens, including polypharmacy14,17,46,57 and high dosing frequency,58–63 are frequently reported as a reason for non-adherence. Polypharmacy is common in patients at risk of CVD due to the multifactorial aetiology of the disease. Furthermore, patients may have one or more co-morbidities that necessitate the use of additional, non-CV medications. In one study, around one-third of patients receiving both antihypertensive and lipid-lowering therapies were adherent to their medication after six months,46 although adherence was improved if both drugs were initiated at the same time.46 It has been suggested that polypharmacy may have an adverse effect on adherence because patients do not understand their complex dosing regimens and/or experience problems in organising their daily schedules to accommodate these regimens.30

Adherence may also be affected by the choice of drug prescribed. For example, adherence rates tend to be higher with the newer classes of antihypertensives, such as angiotensin II blockers, newer calcium channel blockers and angiotensin-converting enzyme inhibitors, than with older drugs, such as thiazide diuretics and non-selective beta-blockers.36,64–69 Similarly, adherence rates tend be higher with statins than with older lipid-lowering therapies.70,71 Increased adherence with newer agents may be related to the improved tolerability profiles of these drugs.

Economic factors also contribute, as high drug costs and the inability of patients to afford them are also occasionally reported as reasons for non-adherence, particularly in developing countries.14,29,72–76

Clinical Implications of Non-adherence

Several studies have identified non-adherence to therapy as an important factor that underlies both poor BP control14,26,50,55,57,72,77 and poor lipid control.29,33,78–81 Clearly, such inadequate control of CV risk factors can lead to serious clinical consequences (see Figure 1).82 Non-adherence has been linked with an increased risk of CV events and mortality. A recent meta-analysis of 21 observational studies of pharmacological therapy in chronic diseases, including predominantly antihypertensive and lipid-lowering therapies, showed that ‘good’ adherence was associated with a significant reduction in the risk of overall mortality compared with ‘poor’ adherence.83

In terms of antihypertensives, in the second Australian National Blood Pressure Study (ANBP2), patients (elderly patients with no prior history of CVD) who adhered to their antihypertensive medication regimen were less likely to experience CV morbidity or death (first CV event or first nonfatal CV event; a fatal other CV event; or a first occurrence of heart failure) than those who were non-adherent.20 Similarly, non-adherence to antihypertensive treatment had a substantial effect on mortality in women (enrolled in the National Heart, Lung and Blood Institute beta- Blocker Heart Attack Trial) who had previously experienced a myocardial infarction (MI).84

In terms of lipid-lowering therapies, patients with hypercholesterolaemia and no history of MI who took ≥75% of their prescribed dose of pravastatin in the West Of Scotland COronary Prevention Study (WOSCOPS), had significantly lower rates of non-fatal MI, revascularisation procedures, death from any cause and CV death compared with those who took <75% of their prescribed dose.85

In another primary prevention study (a nested case-control study) ≥90% adherence to statin therapy was associated with a significant reduction in non-fatal coronary artery disease events compared with <90% adherence.86 In addition, negative effects of non-adherence to lipid-lowering therapy on CV morbidity, CV mortality and all-cause mortality have been reported in large, observational, secondary prevention studies.87–90 Non-adherence to statins has also been shown to increase the risk of all-cause mortality in patients with diabetes in a large observational study.91

In addition to directly affecting CV outcomes, non-adherence also appears to predict treatment discontinuation in patients receiving initial antihypertensive treatment.92 This may be important, as early discontinuation increases the risk of acute MI and stroke.93

Economic Implications of Non-adherence

As well as affecting clinical outcomes in CVD, non-adherence to medication in chronic disease places a considerable burden on healthcare resources. Non-adherence is believed to be responsible for 10% of all hospitalisations and 23% of all nursing home admissions.94 In the US, the annual cost of non-adherence has been estimated at approximately US$300 million (2000 prices).95

Although improved adherence to medication may increase drug acquisition costs, these costs are likely to be balanced by reductions in secondary care expenditure. For example, in patients with HTN and hyperlipidaemia, meta-analyses and observational studies have shown that while ‘good’ adherence is associated with increased drug costs, ‘poor’ adherence leads to more CV events, and hence more physician visits/hospital admissions and longer hospital stays.96–98

Ultimately, it is clear that non-adherence to medication has serious negative implications in terms of both clinical and economic outcomes. Therefore, strategies to improve adherence are essential.

Strategies for Improving Adherence

There are various strategies that can be employed to improve adherence to medication in patients with HTN and/or hyperlipidaemia.

Patient–Physician Communication

The results of several meta-analyses have suggested that behavioural/ motivational, educational and combined/simplified interventions may improve medication adherence to a small extent.58,59,61,62,99–101 While there is little evidence to support the superiority of any single strategy over another, a personalised, intensified, patient-focused programme that involves either frequent contact with healthcare professionals or a combination of interventions appears to be the most effective approach.61,100

This theory was recently evaluated in the Risk Evaluation And Communication Health Outcomes and Utilization Trial (REACH-OUT), which was a randomised study designed to evaluate if a physician-delivered CHD risk evaluation and communication programme (intervention programme) could lower the predicted Framingham 10-year risk of MI or death due to CHD by 10% versus usual care within six months.102 The intervention programme included informing patients of their 10-year risk of MI or death due to CHD, educating patients about modifiable risk factors and risk-factor control and three follow-up phone calls by a physician or study nurse. After six months, mean predicted CHD risk was 12.5% with the intervention programme, and 13.7% with usual care (OR 0.896; p=0.001, adjusted for risk at baseline and other covariates). The proportion of patients achieving both BP and LDL-C targets was significantly higher with the intervention programme (25.4%) than usual care (14.1%; p<0.001). The reasons underlying these improvements are not fully understood. However, the impact of the intervention programme on the knowledge, attitudes and behaviour of patients were assessed by means of a questionnaire completed at baseline and at six months.103 The results of this survey indicated that the programme-mediated improvements in the attitudes and awareness of patients of CHD risk, leading to changes in behaviour with respect to adherence to medication and lifestyle modifications.103

Other studies that have investigated the benefits of assessing and communicating the predicted CVD/CHD risk of patients (with the aim of improving risk factor management) have shown limited benefits.104–106 Ultimately, patient–physician communication intervention programmes need to constantly evolve in order to reflect changes in social attitudes and medical practice.

Simplifying Dosing Regimens

As polypharmacy has been shown to negatively influence patient adherence, it is unsurprising that there is evidence to suggest that simplifying dosing regimens may improve adherence. Several meta-analyses suggest that simplifying the dosing regimen, in particular reducing the dosing frequency, may improve adherence to both antihypertensive and lipid-lowering therapy.58–62,100 Once-daily antihypertensive regimens have been associated with adherence rates exceeding 75%.107

In the Caduet Adherence Research Program and Education (CARPE) study, a retrospective analysis of 4,703 patients at risk of CVD, pharmacy-claims data from a large US pharmacy benefit-management company were used to evaluate adherence to a fixed single-pill combination of amlodipine/atorvastatin (Caduet®; Pfizer Inc.) compared with two-drug regimens.108 Patients were newly initiated on the single-pill combination or concomitant calcium channel blocker and statin therapy (initiated within 30 days of each other regardless of initiation sequence) and were followed up for 180 days commencing at the prescription fill date of the second medication class. After six months, patients taking single-pill amlodipine/atorvastatin were almost twice as likely to achieve adherence compared with patients taking the two compounds separately (OR=1.95, 95% CI=1.80–2.13; p<0.0001).108 Furthermore, the percentage of patients achieving a proportion of days covered (PDC) of ≥80% was higher in the single-pill amlodipine/atorvastatin cohort (67.7%) versus other cohorts (≤49.9%).108 Similarly, in a subset analysis of 3,561 patients followed up for a year, the odds of achieving a PDC of ≥80% was higher in the amlodipine/atorvastatin single-pill cohort versus other cohorts.108

Furthermore, it has been shown that such fixed combinations effectively lower both BP and lipid levels. In the clinical utility of Caduet in simultaneously Achieving Blood Pressure And Lipid Endpoints (CAPABLE) trial (African-Americans with concomitant HTN and dyslipidaemia, and either no additional risk factors, one or more CV factors, or CHD or a CHD-risk equivalent; n=499) it was shown that: 48.3% of patients reached both their BP and LDL-C goals (versus 0.8% at baseline); 56.8% of patients reached BP goals (versus 1.4% at baseline); and 73.7% of patients reached LDL-C goals (versus 28.5% at baseline).109 Likewise, in the Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) outcome study investigating aggressive antihypertensive combination treatment (benazepril plus amlodipine), mean BP fell from 145.2/80.2mmHg to 132.7/74.7mmHg at 12 months of follow-up using the combination pill.110 The benefit of fixed-dose combinations in terms of adherence is supported by several retrospective studies39,47,111,112 and a meta-analysis of fixed-combination medications.113

Finally, because of the associated improvement in disease control and reduction in healthcare utilisation, improved adherence with fixed-dose combinations is associated with lower overall costs of care compared with the drug-free combinations.39,96,112

The Future

Although the problem of non-adherence may not be fully recognised by physicians, the clinical and economic consequences of this phenomenon are severe and multifaceted. The foundation for improving adherence will be to quantify the scale and impact of the problem accurately and disseminate this finding across the wide range of stakeholders. Educational approaches to encourage greater adherence should be aimed at healthcare providers, payers and patients and need to be co-ordinated, consistent and comprehensive. Such approaches should highlight potential economic advantages, which are of greatest interest to payers, clinical efficacy improvements to appeal to the prescribing physician and pharmacist, and for the patient, long-term benefits in terms of reduced CV events.

It is clear that more research, based on prospective clinical data, needs to be undertaken in order to identify effective approaches to improve adherence. Therefore, it is encouraging that the volume of such research is increasing. For example, numerous studies are currently under way assessing approaches such as community pharmacist-led interventions,114 online peer support115 and tools for shared decision-making.116 As reasons for non-adherence vary greatly between patients, the more weapons we have in our armamentarium the more likely we will be able to provide the right solution for each individual patient.

Ultimately, physicians need to understand the importance of improving adherence and have the tools to be able to measure it effectively in order to make decisions regarding medication intensification. Achieving optimal clinical outcomes in the future will be linked closely with the management of patient adherence to treatment, coupled with appropriate intensification/escalation of therapy.

Summary

It is clear that adherence to medication is highly important in terms of clinical and economic outcomes, and incredibly complex in terms of management. Human nature and the pressures of modern living mean that new strategies have to be developed and employed in order to improve adherence. Perhaps paramount among such strategies is patient education and motivation, with the rationale being that an educated and motivated patient is much more likely to follow prescribed treatment interventions. In addition, simplified-dosing regimens can play an important role in improving patient adherence and make the task of managing multiple CV risk factors that little bit easier. Ultimately, optimal clinical and economic outcomes are the result of excellent partnerships between patients and physicians.

References

  1. Arias E, United States life tables 2004, Natl Vital Stat Rep, 2007;56:1–39.
    PubMed
  2. Kung HC, Hoyert DL, Xu J, Murphy SL, Deaths: final data for 2005, Natl Vital Stat Rep, 2008;56:1–120.
    PubMed
  3. Allender S, Scarborough P, Peto V, et al. European cardiovascular disease statistics, accessed 16 July 2008. Available at: www.heartstats.org/datapage asp?id=7683
  4. Kannel WB, Abbott RD, Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study, N Engl J Med, 1984;311:1144–7.
    Crossref | PubMed
  5. Hobbs FD, Erhardt L, Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey, Fam Pract, 2002; 19:596–604.
    Crossref | PubMed
  6. Steinberg BA, Bhatt DL, Mehta S, et al., Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease, Am Heart J, 2008;156: 719–27.
    Crossref | PubMed
  7. Kotseva K, De Backer G, De Bacquer D, et al., Clinical reality of cardiovascular prevention: a comparison between EUROASPIRE II and III in thirteen European regions, Eur Heart J, 2008;29 (Abstract Suppl.):763 (Abstract 4501).
  8. Reiner A, Amouyel P, De Backer G, et al., Treatment of dyslipidaemia in coronary patients in Europe: improving but still inadequate, Eur Heart J, 2008;29 (Abstract Suppl.):761–762 (Abstract 4473).
  9. Erhardt LR, Hobbs FD, A global survey of physicians’ perceptions on cholesterol management: the From The Heart study, Int J Clin Pract, 2007;61:1078–85.
    Crossref | PubMed
  10. Dunbar-Jacob J, Erlen JA, Schlenk EA, et al., Adherence in chronic disease, Annu Rev Nurs Res, 2000;18:48–90.
    PubMed
  11. Sabate E (ed.), World Health Organization, Adherence to Longterm Therapies: Evidence for Action, Geneva: 2003.
  12. Dezii CM, Medication noncompliance: what is the problem?, Manag Care, 2000;9:7–12.
    PubMed
  13. Cramer JA, Benedict A, Muszbek N, et al., The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review, Int J Clin Pract, 2008; 62:76–87.
    Crossref | PubMed
  14. Almas A, Hameed A, Ahmed B, Islam M, Compliance to antihypertensive therapy, J Coll Physicians Surg Pak, 2006;16: 23–6.
    PubMed
  15. Düsing R, Weisser B, Mengden T, Vetter H, Changes in antihypertensive therapy – the role of adverse effects and compliance, Blood Press, 1998;7:313–15.
    Crossref | PubMed
  16. Kressin NR, Wang F, Long J, et al., Hypertensive patients’ race, health beliefs, process of care, and medication adherence, J Gen Intern Med, 2007;22:768–74.
    Crossref | PubMed
  17. Kulkarni SP, Alexander KP, Lytle B, et al., Long-term adherence with cardiovascular drug regimens, Am Heart J, 2006;151: 185–91.
    Crossref | PubMed
  18. Li WW, Stewart AL, Stotts N, Froelicher ES, Cultural factors associated with antihypertensive medication adherence in Chinese immigrants, J Cardiovasc Nurs, 2006;21:354–62.
    Crossref | PubMed
  19. Mann DM, Allegrante JP, Natarajan S, et al., Predictors of adherence to statins for primary prevention, Cardiovasc Drugs Ther, 2007;21:311–6.
    Crossref | PubMed
  20. Nelson MR, Reid CM, Ryan P, et al., Self-reported adherence with medication and cardiovascular disease outcomes in the Second Australian National Blood Pressure Study (ANBP2), Med J Aust, 2006;185:487–9.
    PubMed
  21. Perez-Stable EJ, Salazar R, Issues in achieving compliance with antihypertensive treatment in the Latino population, Clin Cornerstone, 2004;6:49–61.
    PubMed
  22. Ross S, Walker A, MacLeod MJ, Patient compliance in hypertension: role of illness perceptions and treatment beliefs, J Hum Hypertens, 2004;18:607–13.
    Crossref | PubMed
  23. Briesacher BA, Andrade SE, Fouayzi H, Chan KA, Comparison of drug adherence rates among patients with seven different medical conditions, Pharmacotherapy, 2008;28:437–43.
    Crossref | PubMed
  24. Elliott WJ, Optimizing medication adherence in older persons with hypertension, Int Urol Nephrol, 2003;35:557–62.
    Crossref | PubMed
  25. Hyre AD, Krousel-Wood MA, Muntner P, et al., Prevalence and predictors of poor antihypertensive medication adherence in an urban health clinic setting, J Clin Hypertens (Greenwich), 2007; 9:179–86.
    Crossref | PubMed
  26. Morris AB, Li J, Kroenke K, et al., Factors associated with drug adherence and blood pressure control in patients with hypertension, Pharmacotherapy, 2006;26:483–92.
    Crossref | PubMed
  27. Natarajan N, Putnam RW, Yip AM, Frail D, Family practice patients’ adherence to statin medications, Can Fam Physician, 2007;53:2144–5.
    PubMed
  28. Ren XS, Kazis LE, Lee A, et al., Identifying patient and physician characteristics that affect compliance with antihypertensive medications, J Clin Pharm Ther, 2002;27:47–56.
    Crossref | PubMed
  29. Schultz JS, O’Donnell JC, McDonough KL, et al., Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population, Am J Manag Care, 2005;11:306–12.
    PubMed
  30. Munger MA, Van Tassell BW, LaFleur J, Medication nonadherence: an unrecognized cardiovascular risk factor, MedGenMed, 2007;9:58.
    PubMed
  31. Vinker S, Shani M, Baevsky T, Elhayany A, Adherence with statins over 8 years in a usual care setting, Am J Manag Care, 2008;14:388–92.
    PubMed
  32. Fitz-Simon N, Bennett K, Feely J, A review of studies of adherence with antihypertensive drugs using prescription databases, Ther Clin Risk Manag, 2005;1:93–106.
    Crossref | PubMed
  33. Parris ES, Lawrence DB, Mohn LA, Long LB, Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia, Diabetes Care, 2005;28:595–9.
    Crossref | PubMed
  34. Poluzzi E, Strahinja P, Lanzoni M, et al., Adherence to statin therapy and patients’ cardiovascular risk: a pharmacoepidemiological study in Italy, Eur J Clin Pharmacol, 2008;64: 425–32.
    Crossref | PubMed
  35. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A, The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen, J Hypertens, 2004;22:1831–37.
    Crossref | PubMed
  36. Vinker S, Alkalay A, Hoffman RD, et al., Long-term adherence to antihypertensive therapy: a survey in four primary care clinics, Expert Opin Pharmacother, 2008;9:1271–77.
    Crossref | PubMed
  37. Wang PS, Avorn J, Brookhart MA, et al., Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives, Hypertension, 2005;46:273–9.
    Crossref | PubMed
  38. Bosworth HB, Dudley T, Olsen MK, et al., Racial differences in blood pressure control: potential explanatory factors, Am J Med, 2006;119:70.e9–15.
    Crossref | PubMed
  39. Dickson M, Plauschinat CA, Racial differences in medication compliance and healthcare utilization among hypertensive Medicaid recipients: fixed-dose vs free-combination treatment, Ethn Dis, 2008;18:204–9.
    PubMed
  40. Kaplan RC, Bhalodkar NC, Brown EJ Jr, et al., Race, ethnicity, and sociocultural characteristics predict noncompliance with lipid-lowering medications, Prev Med, 2004;39:1249–55.
    Crossref | PubMed
  41. Kramer H, Han C, Post W, et al., Racial/ethnic differences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA), Am J Hypertens, 2004;17:963–70.
    Crossref | PubMed
  42. Monane M, Bohn RL, Gurwitz JH, et al., Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race, Am J Public Health, 1996;86: 1805–8.
    Crossref | PubMed
  43. Raji MA, Kuo YF, Salazar JA, et al., Ethnic differences in antihypertensive medication use in the elderly, Ann Pharmacother, 2004;38:209–14.
    Crossref | PubMed
  44. Sudano JJ Jr, Baker DW, Antihypertensive medication use in Hispanic adults: a comparison with black adults and white adults, Med Care, 2001;39:575–87.
    Crossref | PubMed
  45. Taira DA, Gelber RP, Davis J, et al., Antihypertensive adherence and drug class among Asian Pacific Americans, Ethn Health, 2007;12:265–81.
    Crossref | PubMed
  46. Chapman RH, Benner JS, Petrilla AA, et al., Predictors of adherence with antihypertensive and lipid-lowering therapy, Arch Intern Med, 2005;165:1147–52.
    Crossref | PubMed
  47. Gerbino PP, Shoheiber O, Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents, Am J Health Syst Pharm, 2007;64: 1279–83.
    Crossref | PubMed
  48. Wang PS, Bohn RL, Knight E, et al., Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors, J Gen Intern Med, 2002; 17:504–11.
    Crossref | PubMed
  49. Patel RP, Taylor SD, Factors affecting medication adherence in hypertensive patients, Ann Pharmacother, 2002;36:40–45.
    Crossref | PubMed
  50. Yiannakopoulou ECh, Papadopulos JS, Cokkinos DV, Mountokalakis TD, Adherence to antihypertensive treatment: a critical factor for blood pressure control, Eur J Cardiovasc Prev Rehabil, 2005;12:243–9.
    Crossref | PubMed
  51. Erhardt L, Hobbs FD, Public perceptions of cardiovascular risk in five European countries: the react survey, Int J Clin Pract, 2002; 56:638–44.
    Crossref | PubMed
  52. Bramlage P, Thoenes M, Kirch W, Lenfant C, Clinical practice and recent recommendations in hypertension managementreporting a gap in a global survey of 1259 primary care physicians in 17 countries, Curr Med Res Opin, 2007;23: 783–91.
    Crossref | PubMed
  53. Kjeldsen SE, Naditch-Brule L, Perlini S, et al., Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey, J Hypertens, 2008; 26:2064–70.
    Crossref | PubMed
  54. Feely J, The therapeutic gap – compliance with medication and guidelines, Atherosclerosis, 1999;147(Suppl. 1):S31–7.
    Crossref | PubMed
  55. Ho PM, Magid DJ, Shetterly SM, et al., Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease, Arch Intern Med, 2008;168:271–6.
    Crossref | PubMed
  56. Heisler M, Hogan MM, Hofer TP, et al., When more is not better: treatment intensification among hypertensive patients with poor medication adherence, Circulation, 2008;117: 2884–92.
    Crossref | PubMed
  57. Fung V, Huang J, Brand R, et al., Hypertension treatment in a Medicare population: adherence and systolic blood pressure control, Clin Ther, 2007;29:972–84.
    Crossref | PubMed
  58. Domino FJ, Improving adherence to treatment for hypertension, Am Fam Physician, 2005;71:2089–90.
    PubMed
  59. Iskedjian M, Einarson TR, MacKeigan LD, et al., Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a metaanalysis, Clin Ther, 2002;24:302–16.
    Crossref | PubMed
  60. Leenen FH, Wilson TW, Bolli P, et al., Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring, Can J Cardiol, 1997;13:914–20.
    PubMed
  61. Petrilla AA, Benner JS, Battleman DS, et al., Evidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medications, Int J Clin Pract, 2005;59:1441–51.
    Crossref | PubMed
  62. Schroeder K, Fahey T, Ebrahim S, Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings, Cochrane Database Syst Rev, 2004; CD004804.
    Crossref | PubMed
  63. Wetzels GE, Nelemans P, Schouten JS, Prins MH, Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review, J Hypertens, 2004;22: 1849–55.
    Crossref | PubMed
  64. Kretzer K, Juarez DT, Davis J, Initial antihypertensive prescriptions, switching patterns and adherence among insured patients in Hawai’i, Hawaii Med J, 2008;67:96–9.
    PubMed
  65. Lachaine J, Petrella RJ, Merikle E, Ali F, Choices, persistence and adherence to antihypertensive agents: evidence from RAMQ data, Can J Cardiol, 2008;24:269–73.
    Crossref | PubMed
  66. Monane M, Bohn RL, Gurwitz JH, et al., The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly, Am J Hypertens, 1997;10:697–704.
    Crossref | PubMed
  67. Patel BV, Remigio-Baker RA, Mehta D, et al., Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States, J Clin Hypertens (Greenwich), 2007;9:692–700.
    Crossref | PubMed
  68. Rizzo JA, Simons WR, Variations in compliance among hypertensive patients by drug class: implications for health care costs, Clin Ther, 1997;19:1446–57.
    Crossref | PubMed
  69. Wannemacher AJ, Schepers GP, Townsend KA, Antihypertensive medication compliance in a Veterans Affairs Healthcare System, Ann Pharmacother, 2002;36:986–91.
    Crossref | PubMed
  70. Lachaine J, Rinfret S, Merikle EP, Tarride JE, Persistence and adherence to cholesterol lowering agents: evidence from Régie de l’Assurance Maladie du Québec data, Am Heart J, 2006; 152:164–9.
    Crossref | PubMed
  71. Tsuyuki RT, Bungard TJ, Poor adherence with hypolipidemic drugs: a lost opportunity, Pharmacotherapy, 2001;21:576–82.
    Crossref | PubMed
  72. Amira CO, Okubadejo NU, Factors influencing non-compliance with anti-hypertensive drug therapy in Nigerians, Niger Postgrad Med J, 2007;14:325–9.
    PubMed
  73. Brooks D, Charleston J, Dowie D, et al., Predictors of participant adherence and retention in the African American Study of Kidney Disease and Hypertension, Nephrol Nurs J, 2008;35:133–42.
    PubMed
  74. Elzubier AG, Husain AA, Suleiman IA, Hamid ZA, Drug compliance among hypertensive patients in Kassala, eastern Sudan, East Mediterr Health J, 2000;6:100–105.
    PubMed
  75. Ohene Buabeng K, Matowe L, Plange-Rhule J, Unaffordable drug prices: the major cause of non-compliance with hypertension medication in Ghana, J Pharm Pharm Sci, 2004; 7:350–52.
    PubMed
  76. Stuart B, Zacker C, Who bears the burden of Medicaid drug copayment policies?, Health Aff (Millwood), 1999;18:201–12.
    Crossref | PubMed
  77. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F, Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations, J Manag Care Pharm, 2006;12:239–45.
    Crossref | PubMed
  78. Benner JS, Pollack MF, Smith TW,et al., Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy, Am J Health Syst Pharm, 2005;62: 1468–75.
    Crossref | PubMed
  79. Hollman G, Olsson AG, Ek AC, Disease knowledge and adherence to treatment in patients with familial hypercholesterolemia, J Cardiovasc Nurs, 2006;21:103–8.
    Crossref | PubMed
  80. Mäenpää H, Heinonen OP, Manninen V, Medication compliance and serum lipid changes in the Helsinki Heart Study, Br J Clin Pharmacol, 1991;32:409–15.
    Crossref | PubMed
  81. Mansur AP, Mattar AP, Tsubo CE, et al., Prescription and adherence to statins of patients with coronary artery disease and hypercholesterolemia, Arq Bras Cardiol, 2001;76:111–18.
    PubMed
  82. Ho PM, Rumsfeld JS, Masoudi FA, et al., Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus, Arch Intern Med, 2006;166:1836–41.
    Crossref | PubMed
  83. Simpson SH, Eurich DT, Majumdar SR, et al., A meta-analysis of the association between adherence to drug therapy and mortality, BMJ, 2006;333:15.
    Crossref | PubMed
  84. Gallagher EJ, Viscoli CM, Horwitz RI, The relationship of treatment adherence to the risk of death after myocardial infarction in women, JAMA, 1993;270:742–4.
    Crossref | PubMed
  85. The West of Scotland Coronary Prevention Study, Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study, Eur Heart J, 1997;18: 1718–24.
    Crossref | PubMed
  86. Bouchard MH, Dragomir A, Blais L, et al., Impact of adherence to statins on coronary artery disease in primary prevention, Br J Clin Pharmacol, 2007;63:698–708.
    Crossref | PubMed
  87. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Cardiovascular morbidity associated with nonadherence to statin therapy, Pharmacotherapy, 2005;25:1035–43.
    Crossref | PubMed
  88. Rasmussen JN, Chong A, Alter DA, Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction, JAMA, 2007;297: 177–86.
    Crossref | PubMed
  89. Wei L, Wang J, Thompson P, et al., Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study, Heart, 2002;88:229–33.
    Crossref | PubMed
  90. Wei L, Fahey T, MacDonald TM, Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome, Br J Clin Pharmacol, 2008;66:110–16.
    Crossref | PubMed
  91. Zhang Q, Safford M, Miller D, et al., Short-term statin exposure is associated with reduced all-cause mortality in persons with diabetes, Med Care, 2007;45:308–14.
    Crossref | PubMed
  92. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A, Initial noncompliance with antihypertensive monotherapy is followed by complete discontinuation of antihypertensive therapy, Pharmacoepidemiol Drug Saf, 2006;15:587–93.
    Crossref | PubMed
  93. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, et al., The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke, Curr Med Res Opin, 2008;24:121–7.
    Crossref | PubMed
  94. Task Force for Compliance, Noncompliance with medication regimens: an economic tragedy: emerging issues in pharmaceutical cost containing, Washington, DC, 1994;1–32.
  95. McGhan WF, Peterson AM, Pharmacoeconomic impact of noncompliance, US Pharmacist Impact, 2001;3–13.
  96. Muszbek N, Brixner D, Benedict A, et al., The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review, Int J Clin Pract, 2008; 62:338–51.
    Crossref | PubMed
  97. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS, Impact of medication adherence on hospitalization risk and healthcare cost, Med Care, 2005;43:521–30.
    Crossref | PubMed
  98. Urquhart J, Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens, Pharmacoeconomics, 1999;15:217–28.
    Crossref | PubMed
  99. Peterson AM, Takiya L, Finley R, Meta-analysis of trials of interventions to improve medication adherence, Am J Health Syst Pharm, 2003;60:657–65.
    PubMed
  100. Schedlbauer A, Schroeder K, Fahey T, How can adherence to lipid-lowering medication be improved? A systematic review of randomized controlled trials, Fam Pract, 2007;24:380–87.
    Crossref | PubMed
  101. Takiya LN, Peterson AM, Finley RS, Meta-analysis of interventions for medication adherence to antihypertensives, Ann Pharmacother, 2004;38:1617–24.
    Crossref | PubMed
  102. Benner JS, Erhardt L, Flammer M, et al., A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients’ modifiable risk factor profile, Int J Clin Pract, 2008;62:1484–98.
    Crossref | PubMed
  103. Benner JS, Erhardt L, Flammer M, et al., Improvement in predicted CHD risk with a novel CHD risk evaluation/ communication program is related to patient attitudes and behavior (the REACH OUT Study), Blood, 2008; In press.
  104. Grover SA, Lowensteyn I, Joseph L, et al., Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the CHECK-UP study: a randomized controlled trial, Arch Intern Med, 2007;167:2296–2303.
    Crossref | PubMed
  105. Lowensteyn I, Joseph L, Levinton C, et al., Can computerized risk profiles help patients improve their coronary risk? The results of the Coronary Health Assessment Study (CHAS), Prev Med, 1998;27:730–37.
    Crossref | PubMed
  106. Montgomery AA, Fahey T, Peters TJ, et al., Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: randomised controlled trial, BMJ, 2000;320:686–90.
    Crossref | PubMed
  107. Cramer JA, Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence, Am J Manag Care, 1998;4:1563–8.
    PubMed
  108. Patel BV, Leslie RS, Thiebaud P, et al., Adherence with singlepill amlodipine/atorvastatin vs a two-pill regimen, Vasc Health Risk Manag, 2008;4:673–81.
    PubMed
  109. Flack JM, Victor R, Watson K, et al., Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial, Mayo Clin Proc, 2008;83:35–45.
    Crossref | PubMed
  110. Kjeldsen SE, Jamerson KA, Bakris GL, et al., Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study, Blood Press, 2008;17:7–17.
    Crossref | PubMed
  111. Dezii CM, A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension, Manag Care, 2000;9:2–6.
    PubMed
  112. Taylor AA, Shoheiber O, Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy, Congest Heart Fail, 2003;9:324–32.
    Crossref | PubMed
  113. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH, Fixeddose combinations improve medication compliance: a metaanalysis, Am J Med, 2007;120:713–19.
    Crossref | PubMed
  114. A community pharmacist-led intervention to improve adherence to lipid-lowering treatment, accessed 11 November 2008. Available at: http://clinicaltrials.gov/ct2/show/NCT00493337
  115. Enhancing adherence by building online communities, accessed 11 November 2008. Available at: http://clinicaltrials.gov/ ct2/show/NCT00729040
  116. Shared decision-making: effects on cardiac risk factor modification behavior, accessed 11 November 2008. Available at: http://clinicaltrials.gov/ct2/show/NCT00714935
Previous Volume Article Next Volume Article